Page 28 - Read Online

Page 76 Bhasin et al. J Transl Genet Genom 2024;8:55-76 https://dx.doi.org/10.20517/jtgg.2023.46

cytotoxicity and cytokine secretion. Blood 2006;107:159-66. DOI PubMed PMC
150. Schmohl JU, Felices M, Taras E, Miller JS, Vallera DA. Enhanced ADCC and NK cell activation of an anticarcinoma bispecific
antibody by genetic insertion of a modified IL-15 cross-linker. Mol Ther 2016;24:1312-22. DOI PubMed PMC
151. Felices M, Lenvik TR, Davis ZB, Miller JS, Vallera DA. Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of
tumor cells. In: Somanchi SS, editor. Natural killer cells. New York: Springer; 2016. pp. 333-46. DOI PubMed PMC
152. Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer 2021;21:360-78. DOI
PubMed
153. Shastry M, Gupta A, Chandarlapaty S, Young M, Powles T, Hamilton E. Rise of antibody-drug conjugates: the present and future.
Am Soc Clin Oncol Educ Book 2023;43:e390094. DOI PubMed
154. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
Expert Opin Investig Drugs 2009;18:1001-11. DOI PubMed PMC
155. Kyriakopoulos CE, Eickhoff JC, Ferrari AC, et al. Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-
binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer. Clin Cancer Res 2020;26:5162-71. DOI PubMed
PMC
156. Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a trop-2-directed antibody-drug conjugate, for patients with
epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol 2021;32:746-56. DOI
157. Bidkar AP, Wang S, Bobba KN, et al. Treatment of prostate cancer with CD46-targeted 225 Ac alpha particle radioimmunotherapy.
Clin Cancer Res 2023;29:1916-28. DOI PubMed PMC